影响万古霉素血药浓度因素及临床药师干预对治疗效果的影响

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (522 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the factors that influence plasma vancomycin concentrations and the effect of clinical pharmacist intervention on the therapeutic effect. Methods The clinical data of 120 cases of patients who received vancomycin concentration monitoring in our hospital between July 2018 and July 2019 was retrospectively analyzed. The influencing factors of vancomycin plasma concentrations were determined by Pearson single factor analysis and multiple Logistic regression analysis before the cases were randomly divided into the intervention group and the non-intervention group.The effect of intervention by clinical pharmacists was analyzed. Results (1) The influencing factors of plasma vancomycin concentrations included age, BMI, plasma albumin levels, creatinine clearance rate, moderate and severe peripheral edema, abnormal liver function and pre-existing diseases according to univariate analysis(P<0.05). (2) The above-mentioned factors with statistically significant differences by univariate analysis were put into the multiple Logistic regression model, and the results showed that age, moderate and severe peripheral edema, abnormal renal function and BMI were factors that affected the plasma concentration of vancomycin (P<0.05). (3) The compliance rate of serum drug concentrations, 30d mortality rate and incidence of adverse reactions in the intervention group were 62.79%, 2.33% and 6.98% respectively, which were significantly different from those of the control group [34.88%, 9.30% and 18.60% respectively] (P<0.05). Conclusions The influencing factors of blood concentrations of vancomycin include age, moderate and severe peripheral edema, abnormal renal function and BMI. Therefore, clinical pharmacists should strengthen the blood concentration intervention to improve the drug effect.

Key words： vancomycin blood concentration influencing factors clinical pharmacist intervention

Received: 30 December 2019

ZTFLH:

R979.9

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIAN Yufei
	YANG Yupeng
	WANG Yanze
	ZHANG Yue
	QIU Xuejia
	FANG Lingzhi
	LIU Hongtao

Cite this article:

LIAN Yufei,YANG Yupeng,WANG Yanze等. Factors influencing plasma vancomycin concentrations and effect of clinical pharmacist intervention on the clinical outcome[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2020, 31(6): 476-478.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2020/V31/I6/476

[1]	陈婷,黄晓会,陈霁,等. 美罗培南在脓毒血症患者体内的药动学研究[J]. 中国医药,2017, 12(4): 603-606.
[2]	张慧芳,王瑞兰,舒文,等. 成人患者万古霉素血药浓度监测及有效性和安全性评估[J].中华危重病急救医学,2018, 30(6): 538-543.
[3]	唐喆,曹静,帅维维,等. 新生儿万古霉素血药谷浓度影响因素分析 [J]. 中国抗生素杂志,2019, 44(4): 493-502.
[4]	林忠,陈敏方,崔可,等. 中国成年感染患者万古霉素群体药动学研究 [J]. 中国现代应用药学,2017, 34(1): 101-106.
[5]	吴汀溪,续畅,沈素. 万古霉素血药浓度对老年患者肾功能的影响 [J]. 中国医药导报,2017, 14(6): 160-163.
[6]	黄兴富,童伟,吴静,等. 万古霉素在重症感染患者的药动学 [J]. 医药导报,2018, 37(6): 745-749.
[7]	万古霉素临床应用剂量专家组. 万古霉素临床应用剂量中国专家共识 [J]. 中华传染病杂志,2012, 30(11): 641-645.
[8]	刘素琴,沈国琴. 我院ICU老年感染患者万古霉素血药谷浓度的监测结果分析 [J]. 中国药房,2018, 29(24): 3417-3420.
[9]	施金虎,孙辉明. 万古霉素与头孢他啶对老年心力衰竭合并肺部感染患者炎症因子及降钙素原的影响 [J]. 药物评价研究,2017, 40(11): 1614-1617.
[10]	方洁,何乐,程齐俭.中国成人万古霉素给药剂量的商榷[J].中国感染与化疗杂志,2014,14(4):291-294.
[11]	李静静,刘艺茜,唐莲,等. 新生儿万古霉素的群体药动学研究[J]. 中国药学杂志,2017, 52(16): 1434-1441.
[12]	梁培,郭晓芳.高肌酐清除率重症患者万古霉素血药浓度监测分析[J].药学与临床研究,2017,25(6):493-496.
[13]	申庆荣,李刚,卢秋玉,等.万古霉素血药浓度的影响因素分析[J].中国抗生素杂志,2017,42(5):429-434.
[14]	朱卫江,姜文燕,蒋玉凤.ICU患者万古霉素血药浓度监测与个体化给药方案调整[J].中国药师,2017,20(8):1437-1439.
[15]	何娟,毛恩强,景峰,等. SAP患者万古霉素的药代动力学及其影响因素:附7年的数据分析 [J]. 中华危重病急救医学,2017, 29(6): 491-495.
[16]	李静静,刘艺茜,唐莲,等.新生儿万古霉素的群体药动学研究[J].中国药学杂志, 2017, 52(16): 1434-1441.
[17]	Moffett B S, Hilvers P S, Dinh K, et al. Vancomycinassociated kidney injury in pediatric cardiac intensive care patients[J]. Congenit Heart Dis, 2015, 10(1): E6-E10.